
Zanidatamab exhibits ‘promising’ efficacy in advanced HER2-positive biliary tract cancer
Results of the phase 2B HERIZON-BTC-01 study showed that zanidatamab exhibited durable antitumor activity in patients with previously treated advanced HER2-amplified biliary tract cancer. More than half of the patients who received zanidatamab monotherapy survived at least a year, with a median overall survival that exceeded 15 months. The study included 87 participants with various…